WASHINGTON , June 11, 2025 (GLOBE NEWSWIRE) -- ASP Isotopes Inc. NASDAQ: ASPI ("ASP Isotopes” or the “Company”), an advanced materials company dedicated to the development of technology and processes for the production of isotopes for use in multiple industries, today announced the appointment of Dr. Ryno Pretorius, PhD as Chief Executive Officer of Quantum Leap Energy LLC (QLE), the Company’s subsidiary that is pursuing an initiative to develop and commercialize advanced nuclear fuels, such as High Assay L ...

WASHINGTON, June 04, 2025 (GLOBE NEWSWIRE) -- ASP Isotopes Inc. NASDAQ: ASPI ("ASP Isotopes” or the “Company”), an advanced materials company dedicated to the development of technology and processes for the production of isotopes for use in multiple industries, today announced that it will host an Investor Access Event in South Africa from June 16-18, 2025. **There is also the possibility of adding an extra day to the trip and visiting the Renergen Virginia Gas Project on June 19th – please let us know if y ...

Core Insights - ASP Isotopes Inc. has commenced the production of highly enriched Ytterbium-176, a critical material for oncology treatments, following the successful commissioning of its Quantum Enrichment facility in Pretoria, South Africa [3][4][5] - The company aims to achieve 99.75% enrichment for Ytterbium-176 and plans to offer it for commercial sale in 2025 [5][8] - ASP Isotopes is also planning to construct additional enrichment facilities for Nickel-64, Gadolinium-160, and Lithium-6/7 based on the success of the Ytterbium-176 facility [10][12] Company Developments - The Ytterbium-176 enrichment facility is the company's third in South Africa and utilizes a novel laser-based Quantum Enrichment method, which is believed to be more efficient and scalable than traditional methods [4][5] - The construction phase of the facility took only 8 months, significantly shorter than the anticipated 18 months, and the commissioning phase took 6 months [5] - The company has received considerable interest from customers in North America, Europe, and Asia for Ytterbium-176, indicating a strong demand for this isotope [9] Market Context - The beta-emitting radiopharmaceutical market, including drugs like Novartis' Pluvicto, is projected to exceed $15 billion annually in the next decade, with consensus forecasts for Pluvicto alone exceeding $4 billion [8] - There are significant supply-side challenges for essential radioisotopes, with reports of treatment delays due to drug availability [8][9] - ASP Isotopes aims to be one of the few suppliers of commercial quantities of Ytterbium-176 and similar isotopes in the Western world, addressing current supply chain issues [8][9] Future Plans - The company is in discussions with nuclear regulatory authorities for the authorization to construct HALEU uranium enrichment facilities using Quantum Enrichment technology in South Africa and other countries [2][16] - There is an anticipated demand for Lithium-6 and Lithium-7 for future nuclear fusion power plants and advanced nuclear reactors, with no current Western producers of Lithium-6 in commercial quantities [13][15] - The company believes its Quantum Enrichment process could produce HALEU at competitive prices, potentially accelerating the adoption of new nuclear energy solutions [14][15]